Literature DB >> 28089341

Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer.

Waseem Lutfi1, Mark S Talamonti1, Olga Kantor2, Chi-Hsiung Wang1, Susan J Stocker1, David J Bentrem3, Kevin K Roggin2, David J Winchester1, Robert Marsh1, Richard A Prinz1, Marshall S Baker4.   

Abstract

OBJECTIVE: Neoadjuvant protocols for early stage pancreatic adenocarcinoma (PDAC) frequently involve external beam radiation used in combination with systemic chemotherapy. The benefit of radiation in these protocols has not been determined.
METHODS: We examined patients with stage I and II PDAC within the National Cancer Data Base between 2006 and 2012. Propensity score matching was used to compare patients receiving neoadjuvant chemotherapy including radiation (NCRT) to those receiving neoadjuvant chemotherapy without radiation (NCT) prior to pancreaticoduodenectomy.
RESULTS: Prior to matching, NCRT patients had higher rates of T3 tumors (P = 0.046) and vascular abutment (P < 0.001). Propensity score matching (1:1) yielded 397 patients per group. Patients treated with NCRT were more likely to have node negative resections (P < 0.001) but had increased rates of 90-day mortality (P = 0.015) and demonstrated a trend towards shorter overall survival (P = 0.0502) than those receiving NCT.
CONCLUSION: In early stage PDAC, the addition of radiation to NCT is often utilized with more advanced disease and is associated with higher perioperative mortality and no long-term overall survival benefit.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neoadjuvant therapy; Overall survival; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Pancreaticoduodenectomy; Radiation therapy

Mesh:

Year:  2016        PMID: 28089341     DOI: 10.1016/j.amjsurg.2016.11.039

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.

Authors:  Quisette P Janssen; Jacob L van Dam; Laura R Prakash; Deesje Doppenberg; Christopher H Crane; Casper H J van Eijck; Susannah G Ellsworth; William R Jarnagin; Eileen M O'Reilly; Alessandro Paniccia; Marsha Reyngold; Marc G Besselink; Matthew H G Katz; Ching-Wei D Tzeng; Amer H Zureikat; Bas Groot Koerkamp; Alice C Wei
Journal:  J Natl Compr Canc Netw       Date:  2022-07       Impact factor: 12.693

Review 2.  Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.

Authors:  Stefan Heinrich; Hauke Lang
Journal:  Int J Mol Sci       Date:  2017-07-26       Impact factor: 5.923

Review 3.  Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Morgan Bonds; Flavio G Rocha
Journal:  J Clin Med       Date:  2019-08-12       Impact factor: 4.241

Review 4.  Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, Radiological and NAT Regimen Prognostic Factors-Literature Review.

Authors:  Aiste Gulla; Daisuke Hashimoto; Doris Wagner; Ryte Damaseviciute; Kestutis Strupas; Sohei Satoi
Journal:  Medicina (Kaunas)       Date:  2022-06-01       Impact factor: 2.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.